Cognition Therapeutics Inc (CGTX)vsBeiGene, Ltd. (ONC)
CGTX
Cognition Therapeutics Inc
$0.74
-1.28%
HEALTHCARE · Cap: $69.17M
ONC
BeiGene, Ltd.
$371.56
-0.48%
HEALTHCARE · Cap: $42.96B
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 10.7% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 64/100 (C+).
CGTX
Avoid22
out of 100
Grade: F
ONC
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CGTX.
Margin of Safety
+79.6%
Fair Value
$1720.81
Current Price
$371.56
$1349.25 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Earnings expanding 166.7% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 29.6% year-over-year
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 8.1x book value
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : CGTX
The strongest argument for CGTX centers on Debt/Equity, Price/Book.
Bull Case : ONC
The strongest argument for ONC centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 29.6% demonstrates continued momentum. PEG of 0.77 suggests the stock is reasonably priced for its growth.
Bear Case : CGTX
The primary concerns for CGTX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ONC
The primary concerns for ONC are Price/Book, P/E Ratio, Altman Z-Score. A P/E of 67.5x leaves little room for execution misses.
Key Dynamics to Monitor
CGTX profiles as a value stock while ONC is a growth play — different risk/reward profiles.
CGTX carries more volatility with a beta of 1.80 — expect wider price swings.
ONC is growing revenue faster at 29.6% — sustainability is the question.
ONC generates stronger free cash flow (596M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (64/100 vs 22/100) and 29.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cognition Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of small molecule therapies targeting age-related degenerative diseases and disorders of the central nervous system and retina. The company is headquartered in Purchase, New York.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?